Mitochondrial medicine and the neurodegenerative mitochondriopathies

Pharmaceuticals

Volumn 2, Issue 3, 2009, Pages 150-167

  Swerdlow, Russell H ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Mitochondria; Mitochondrial biogenesis; Mitochondriopathies; Neurodegenerative diseases; Oxidative stress

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; CHOLINESTERASE INHIBITOR; DIMEBON; KETASYN; MEDIUM CHAIN TRIACYLGLYCEROL; MINOCYCLINE; NICOTINIC ACID; PLACEBO; RESVERATROL; RIBOFLAVIN; ROSIGLITAZONE; THIAMINE; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIOXIDANT ACTIVITY; ARTICLE; BIOGENESIS; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; MITOCHONDRIAL PERMEABILITY; OXIDATIVE STRESS; TREATMENT DURATION; TREATMENT INDICATION; VITAMIN SUPPLEMENTATION;

EID: 74549210060     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph2030150     Document Type: Article

References (107)

1. Swerdlow, R.H. Is aging part of Alzheimer's disease, or is Alzheimer's disease part of aging? Neurobiol. Aging 2007, 28, 1465-1480.
2. McKeith, I.G.; Galasko, D.; Kosaka, K.; Perry, E.K.; Dickson, D.W.; Hansen, L.A.; Salmon, D.P.; Lowe, J.; Mirra, S.S.; Byrne, E.J.; Lennox, G.; Quinn, N.P.; Edwardson, J.A.; Ince, P.G.; Bergeron, C.; Burns, A.; Miller, B.L.; Lovestone, S.; Collerton, D.; Jansen, E.N.; Ballard, C.; de Vos, R.A.; Wilcock, G.K.; Jellinger, K.A.; Perry, R.H. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 1996, 47, 1113-1124.
3. Swerdlow, R.H. Treating neurodegeneration by modifying mitochondria: Potential solutions to a "complex" problem. Antioxid. Redox Signal 2007, 9, 1591-1603.
4. Swerdlow, R.H. The Neurodegenerative Mitochondriopathies. J. Alzheimers Dis. 2009.
5. Swerdlow, R.H.; Kish, S.J. Mitochondria in Alzheimer's disease. Int. Rev. Neurobiol. 2002, 53, 341-385.
6. Parker, W.D., Jr.; Filley, C.M.; Parks, J.K. Cytochrome oxidase deficiency in Alzheimer's disease. Neurology 1990, 40, 1302-1303.
7. Swerdlow, R.H. Mitochondria in cybrids containing mtDNA from persons with mitochondriopathies. J. Neurosci. Res. 2007, 85, 3416-3428.
8. Swerdlow, R.H.; Parks, J.K.; Cassarino, D.S.; Maguire, D.J.; Maguire, R.S.; Bennett, J.P., Jr.; Davis, R.E.; Parker, W.D., Jr. Cybrids in Alzheimer's disease: A cellular model of the disease? Neurology 1997, 49, 918-925.
9. Cardoso, S.M.; Santana, I.; Swerdlow, R.H.; Oliveira, C.R. Mitochondria dysfunction of Alzheimer's disease cybrids enhances Abeta toxicity. J. Neurochem. 2004, 89, 1417-1426.
10. Hirai, K.; Aliev, G.; Nunomura, A.; Fujioka, H.; Russell, R.L.; Atwood, C.S.; Johnson, A.B.; Kress, Y.; Vinters, H.V.; Tabaton, M.; Shimohama, S.; Cash, A.D.; Siedlak, S.L.; Harris, P.L.; Jones, P.K.; Petersen, R.B.; Perry, G.; Smith, M.A. Mitochondrial abnormalities in Alzheimer's disease. J. Neurosci. 2001, 21, 3017-3023.
11. Wang, X.; Su, B.; Lee, H.G.; Li, X.; Perry, G.; Smith, M.A.; Zhu, X. Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J. Neurosci. 2009, 29, 9090-9103.
12. Reddy, P.H.; McWeeney, S.; Park, B.S.; Manczak, M.; Gutala, R.V.; Partovi, D.; Jung, Y.; Yau, V.; Searles, R.; Mori, M.; Quinn, J. Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: Up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. Hum. Mol. Genet. 2004, 13, 1225-1240.
13. Yao, J.; Irwin, R.W.; Zhao, L.; Nilsen, J.; Hamilton, R.T.; Brinton, R.D. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2009, 106, 14670-14675.
14. Du, H.; Guo, L.; Fang, F.; Chen, D.; Sosunov, A.A.; McKhann, G.M.; Yan, Y.; Wang, C.; Zhang, H.; Molkentin, J.D.; Gunn-Moore, F.J.; Vonsattel, J.P.; Arancio, O.; Chen, J.X.; Yan, S. D. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat. Med. 2008, 14, 1097-1105.
15. Lustbader, J.W.; Cirilli, M.; Lin, C.; Xu, H.W.; Takuma, K.; Wang, N.; Caspersen, C.; Chen, X.; Pollak, S.; Chaney, M.; Trinchese, F.; Liu, S.; Gunn-Moore, F.; Lue, L.F.; Walker, D.G.; Kuppusamy, P.; Zewier, Z.L.; Arancio, O.; Stern, D.; Yan, S.S.; Wu, H. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 2004, 304, 448-452.
16. Anandatheerthavarada, H.K.; Devi, L. Amyloid precursor protein and mitochondrial dysfunction in Alzheimer's disease. Neuroscientist 2007, 13, 626-638.
17. Caspersen, C.; Wang, N.; Yao, J.; Sosunov, A.; Chen, X.; Lustbader, J.W.; Xu, H.W.; Stern, D.; McKhann, G.; Yan, S.D. Mitochondrial Abeta: A potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J. 2005, 19, 2040-2041.
18. Devi, L.; Prabhu, B.M.; Galati, D.F.; Avadhani, N.G.; Anandatheerthavarada, H.K. Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction. J. Neurosci. 2006, 26, 9057-9068.
19. Gabuzda, D.; Busciglio, J.; Chen, L. B.; Matsudaira, P.; Yankner, B.A. Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J. Biol. Chem. 1994, 269, 13623-13628.
20. Khan, S.M.; Cassarino, D.S.; Abramova, N.N.; Keeney, P.M.; Borland, M.K.; Trimmer, P.A.; Krebs, C.T.; Bennett, J.C.; Parks, J.K.; Swerdlow, R.H.; Parker, W.D., Jr.; Bennett, J.P., Jr. Alzheimer's disease cybrids replicate beta-amyloid abnormalities through cell death pathways. Ann. Neurol. 2000, 48, 148-155.
21. Swerdlow, R.H.; Khan, S.M. A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. Med. Hypotheses 2004, 63, 8-20.
22. Swerdlow, R.H.; Khan, S.M. The Alzheimer's disease mitochondrial cascade hypothesis: An update. Exp. Neurol. 2009, 218, 308-315.
23. Parker, W.D., Jr.; Boyson, S.J.; Parks, J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 1989, 26, 719-723.
24. Arduino, D.M.; Esteves, A.R.; Oliveira, C.R.; Cardoso, S.M. Mitochondrial Metabolism Modulation: A New Therapeutic Approach for Parkinson's Disease. CNS Neurol. Disord. Drug Targets 2009.
25. Betarbet, R.; Sherer, T.B.; MacKenzie, G.; Garcia-Osuna, M.; Panov, A.V.; Greenamyre, J.T., Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 2000, 3, 1301-1306.
26. Langston, J.W.; Ballard, P.; Tetrud, J.W.; Irwin, I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219, 979-980.
27. Swerdlow, R.H.; Parks, J.K.; Miller, S.W.; Tuttle, J.B.; Trimmer, P.A.; Sheehan, J.P.; Bennett, J.P., Jr.; Davis, R.E.; Parker, W.D., Jr. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann. Neurol. 1996, 40, 663-671.
28. Esteves, A.R.; Domingues, A.F.; Ferreira, I.L.; Januario, C.; Swerdlow, R.H.; Oliveira, C.R.; Cardoso, S.M. Mitochondrial function in Parkinson's disease cybrids containing an nt2 neuronlike nuclear background. Mitochondrion 2008, 8, 219-228.
29. Esteves, A.R.; Arduino, D.M.; Swerdlow, R.H.; Oliveira, C.R.; Cardoso, S.M. Oxidative Stress involvement in alpha-synuclein oligomerization in Parkinsons disease cybrids. Antioxid. Redox Signal 2008.
30. Bender, A.; Krishnan, K.J.; Morris, C.M.; Taylor, G.A.; Reeve, A.K.; Perry, R.H.; Jaros, E.; Hersheson, J.S.; Betts, J.; Klopstock, T.; Taylor, R.W.; Turnbull, D.M. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat. Genet. 2006, 38, 515-517.
31. Kraytsberg, Y.; Kudryavtseva, E.; McKee, A.C.; Geula, C.; Kowall, N.W.; Khrapko, K. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat. Genet. 2006, 38, 518-520.
32. Parker, W.D., Jr.; Parks, J.K. Mitochondrial ND5 mutations in idiopathic Parkinson's disease. Biochem. Biophys. Res. Commun. 2005, 326, 667-669.
33. Smigrodzki, R.; Parks, J.; Parker, W.D. High frequency of mitochondrial complex I mutations in Parkinson's disease and aging. Neurobiol. Aging 2004, 25, 1273-1281.
34. Beal, M.F. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol. 1995, 38, 357-366.
35. Bueler, H. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease. Exp. Neurol. 2009, 218, 235-246.
36. Swerdlow, R.H.; Parks, J.K.; Cassarino, D.S.; Trimmer, P.A.; Miller, S.W.; Maguire, D.J.; Sheehan, J.P.; Maguire, R.S.; Pattee, G.; Juel, V.C.; Phillips, L.H.; Tuttle, J.B.; Bennett, J.P., Jr.; Davis, R.E.; Parker, W.D., Jr. Mitochondria in sporadic amyotrophic lateral sclerosis. Exp. Neurol. 1998, 153, 135-142.
37. Swerdlow, R.H.; Parks, J.K.; Pattee, G.; Parker, W.D., Jr. Role of mitochondria in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2000, 1, 185-190.
38. Albers, D.S.; Swerdlow, R.H.; Manfredi, G.; Gajewski, C.; Yang, L.; Parker, W.D., Jr.; Beal, M.F. Further evidence for mitochondrial dysfunction in progressive supranuclear palsy. Exp. Neurol. 2001, 168, 196-198.
39. Swerdlow, R.H.; Golbe, L.I.; Parks, J.K.; Cassarino, D.S.; Binder, D.R.; Grawey, A.E.; Litvan, I.; Bennett, J.P., Jr.; Wooten, G.F.; Parker, W.D. Mitochondrial dysfunction in cybrid lines expressing mitochondrial genes from patients with progressive supranuclear palsy. J. Neurochem. 2000, 75, 1681-1684.
40. Browne, S.E.; Beal, M.F. The energetics of Huntington's disease. Neurochem. Res. 2004, 29, 531-546.
41. Cui, L.; Jeong, H.; Borovecki, F.; Parkhurst, C.N.; Tanese, N.; Krainc, D. Transcriptional repression of PGC-alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006, 127, 59-69.
42. Panov, A.V.; Gutekunst, C.A.; Leavitt, B.R.; Hayden, M.R.; Burke, J.R.; Strittmatter, W.J.; Greenamyre, J.T. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 2002, 5, 731-736.
43. Koutnikova, H.; Campuzano, V.; Foury, F.; Dolle, P.; Cazzalini, O.; Koenig, M. Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin. Nat. Genet. 1997, 16, 345-351.
44. Pandolfo, M. Friedreich ataxia. Arch. Neurol. 2008, 65, 1296-1303.
45. Luft, R. The development of mitochondrial medicine. Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 8731-8738.
46. Mattson, M. P. Apoptosis in neurodegenerative disorders. Nat. Rev. Mol. Cell Biol. 2000, 1, 120-129.
47. Aliev, G.; Liu, J.; Shenk, J.C.; Fischbach, K.; Pacheco, G.J.; Chen, S.G.; Obrenovich, M.E.; Ward, W.F.; Richardson, A.G.; Smith, M.A.; Gasimov, E.; Perry, G.; Ames, B.N. Neuronal mitochondrial amelioration by feeding acetyl-L-carnitine and lipoic acid to aged rats. J. Cell Mol. Med. 2009, 13, 320-333.
48. Rosca, M.G.; Lemieux, H.; Hoppel, C.L. Mitochondria in the elderly: Is acetylcarnitine a rejuvenator? Adv. Drug Deliv. Rev. 2009.
49. Veech, R.L.; Chance, B.; Kashiwaya, Y.; Lardy, H.A.; Cahill, G.F., Jr. Ketone bodies, potential therapeutic uses. IUBMB Life 2001, 51, 241-247.
50. Adhihetty, P.J.; Beal, M.F. Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases. Neuromolecular Med. 2008, 10, 275-290.
51. Saelens, X.; Festjens, N.; Vande Walle, L.; van Gurp, M.; van Loo, G.; Vandenabeele, P. Toxic proteins released from mitochondria in cell death. Oncogene 2004, 23, 2861-2874.
52. Crompton, M.; Virji, S.; Doyle, V.; Johnson, N.; Ward, J.M. The mitochondrial permeability transition pore. Biochem. Soc. Symp. 1999, 66, 167-179.
53. Lemasters, J.J.; Theruvath, T.P.; Zhong, Z.; Nieminen, A.L. Mitochondrial calcium and the permeability transition in cell death. Biochim. Biophys. Acta 2009, 1787, 1395-1401.
54. Haller, R.G.; Vissing, J. Drilling for energy in mitochondrial disease. Arch. Neurol. 2009, 66, 931-932.
55. Mestre, T.; Ferreira, J.; Coelho, M.M.; Rosa, M.; Sampaio, C. Therapeutic interventions for disease progression in Huntington's disease. Cochrane Database Syst. Rev. 2009, CD006455.
56. Swerdlow, R.; Marcus, D.M.; Landman, J.; Harooni, M.; Freedman, M.L. Brain glucose and ketone body metabolism in patients with Alzheimer's disease. Clin. Res. 1989, 37, 461A.
57. Henderson, S.T.; Vogel, J.L.; Barr, L.J.; Garvin, F.; Jones, J.J.; Costantini, L.C. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: A randomized, double-blind, placebo-controlled, multicenter trial. Nutr. Metab. (Lond) 2009, 6, 31.
58. Shults, C.W.; Oakes, D.; Kieburtz, K.; Beal, M.F.; Haas, R.; Plumb, S.; Juncos, J.L.; Nutt, J.; Shoulson, I.; Carter, J.; Kompoliti, K.; Perlmutter, J.S.; Reich, S.; Stern, M.; Watts, R.L.; Kurlan, R.; Molho, E.; Harrison, M.; Lew, M. Effects of coenzyme Q10 in early Parkinson disease: Evidence of slowing of the functional decline. Arch. Neurol. 2002, 59, 1541-1550.
59. Kearney, M.; Orrell, R.W.; Fahey, M.; Pandolfo, M. Antioxidants and other pharmacological treatments for Friedreich ataxia. Cochrane Database Syst. Rev. 2009, CD007791.
60. Mariotti, C.; Solari, A.; Torta, D.; Marano, L.; Fiorentini, C.; Di Donato, S. Idebenone treatment in Friedreich patients: One-year-long randomized placebo-controlled trial. Neurology 2003, 60, 1676-1679.
61. Stamelou, M.; Reuss, A.; Pilatus, U.; Magerkurth, J.; Niklowitz, P.; Eggert, K. M.; Krisp, A.; Menke, T.; Schade-Brittinger, C.; Oertel, W.H.; Hoglinger, G.U. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: A randomized, placebo-controlled trial. Mov. Disord. 2008, 23, 942-949.
62. Engelhart, M.J.; Geerlings, M.I.; Ruitenberg, A.; van Swieten, J.C.; Hofman, A.; Witteman, J. C.; Breteler, M.M. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 2002, 287, 3223-3229.
63. Engelhart, M.J.; Ruitenberg, A.; Meijer, J.; Kiliaan, A.; van Swieten, J.C.; Hofman, A.; Witteman, J.C.; Breteler, M.M. Plasma levels of antioxidants are not associated with Alzheimer's disease or cognitive decline. Dement. Geriatr. Cogn. Disord. 2005, 19, 134-139.
64. Boothby, L.A.; Doering, P.L. Vitamin C and vitamin E for Alzheimer's disease. Ann. Pharmacother. 2005, 39, 2073-2080.
65. Sano, M.; Ernesto, C.; Thomas, R.G.; Klauber, M.R.; Schafer, K.; Grundman, M.; Woodbury, P.; Growdon, J.; Cotman, C.W.; Pfeiffer, E.; Schneider, L.S.; Thal, L.J. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N. Engl. J. Med. 1997, 336, 1216-1222.
66. Doody, R.S.; Stevens, J.C.; Beck, C.; Dubinsky, R.M.; Kaye, J.A.; Gwyther, L.; Mohs, R.C.; Thal, L.J.; Whitehouse, P.J.; DeKosky, S.T.; Cummings, J.L. Practice parameter: Management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001, 56, 1154-1166.
67. Miller, E.R., 3rd; Pastor-Barriuso, R.; Dalal, D.; Riemersma, R.A.; Appel, L.J.; Guallar, E. Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med. 2005, 142, 37-46.
68. Ristow, M.; Zarse, K.; Oberbach, A.; Kloting, N.; Birringer, M.; Kiehntopf, M.; Stumvoll, M.; Kahn, C.R.; Bluher, M. Antioxidants prevent health-promoting effects of physical exercise in humans. Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 8665-8670.
69. Bjelakovic, G.; Nikolova, D.; Gluud, L.L.; Simonetti, R.G.; Gluud, C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: Systematic review and meta-analysis. JAMA 2007, 297, 842-857.
70. Zhu, S.; Stavrovskaya, I.G.; Drozda, M.; Kim, B.Y.; Ona, V.; Li, M.; Sarang, S.; Liu, A.S.; Hartley, D.M.; Wu, D.C.; Gullans, S.; Ferrante, R.J.; Przedborski, S.; Kristal, B.S.; Friedlander, R.M. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002, 417, 74-78.
71. Gordon, P.H.; Moore, D.H.; Miller, R.G.; Florence, J.M.; Verheijde, J.L.; Doorish, C.; Hilton, J.F.; Spitalny, G.M.; MacArthur, R.B.; Mitsumoto, H.; Neville, H.E.; Boylan, K.; Mozaffar, T.; Belsh, J.M.; Ravits, J.; Bedlack, R.S.; Graves, M.C.; McCluskey, L.F.; Barohn, R.J.; Tandan, R. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: A phase III randomised trial. Lancet Neurol. 2007, 6, 1045-1053.
72. Finkel, T. Reactive oxygen species and signal transduction. IUBMB Life 2001, 52, 3-6.
73. Finkel, T. Oxidant signals and oxidative stress. Curr. Opin. Cell Biol. 2003, 15, 247-254.
74. Armstrong, J.S. Mitochondrial medicine: Pharmacological targeting of mitochondria in disease. Br. J. Pharmacol. 2007, 151, 1154-1165.
75. Reddy, P.H. Mitochondrial oxidative damage in aging and Alzheimer's disease: Implications for mitochondrially targeted antioxidant therapeutics. J. Biomed. Biotechnol. 2006, 2006, 31372.
76. Kelso, G.F.; Porteous, C.M.; Coulter, C.V.; Hughes, G.; Porteous, W.K.; Ledgerwood, E.C.; Smith, R.A.; Murphy, M.P. Selective targeting of a redox-active ubiquinone to mitochondria within cells: Antioxidant and antiapoptotic properties. J. Biol. Chem. 2001, 276, 4588-4596.
77. Doody, R.S.; Gavrilova, S.I.; Sano, M.; Thomas, R.G.; Aisen, P.S.; Bachurin, S.O.; Seely, L.; Hung, D. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: A randomised, double-blind, placebo-controlled study. Lancet 2008, 372, 207-215.
78. Bachurin, S.O.; Shevtsova, E.P.; Kireeva, E.G.; Oxenkrug, G.F.; Sablin, S.O. Mitochondria as a target for neurotoxins and neuroprotective agents. Ann. NY Acad. Sci. 2003, 993, 334-344; discussion 345-339.
79. Navarro, A.; Boveris, A. The mitochondrial energy transduction system and the aging process. Am. J. Physiol. Cell Physiol. 2007, 292, C670-686.
80. Boveris, A.; Navarro, A. Systemic and mitochondrial adaptive responses to moderate exercise in rodents. Free Radic. Biol. Med. 2008, 44, 224-229.
81. Civitarese, A.E.; Smith, S.R.; Ravussin, E. Diet, energy metabolism and mitochondrial biogenesis. Curr. Opin. Clin. Nutr. Metab. Care 2007, 10, 679-687.
82. Fernstrom, M.; Tonkonogi, M.; Sahlin, K. Effects of acute and chronic endurance exercise on mitochondrial uncoupling in human skeletal muscle. J. Physiol. 2004, 554, 755-763.
83. Hepple, R.T. Why eating less keeps mitochondria working in aged skeletal muscle. Exerc. Sport Sci. Rev. 2009, 37, 23-28.
84. Holloszy, J.O. Adaptation of skeletal muscle to endurance exercise. Med. Sci. Sports 1975, 7, 155-164.
85. Hood, D.A. Mechanisms of exercise-induced mitochondrial biogenesis in skeletal muscle. Appl. Physiol. Nutr. Metab. 2009, 34, 465-472.
86. Hoppeler, H.; Fluck, M. Plasticity of skeletal muscle mitochondria: Structure and function. Med. Sci. Sports Exerc. 2003, 35, 95-104.
87. Lambert, A.J.; Wang, B.; Yardley, J.; Edwards, J.; Merry, B.J. The effect of aging and caloric restriction on mitochondrial protein density and oxygen consumption. Exp. Gerontol. 2004, 39, 289-295.
88. Weindruch, R.; Sohal, R.S. Seminars in medicine of the Beth Israel Deaconess Medical Center. Caloric intake and aging. N. Engl. J. Med. 1997, 337, 986-994.
89. Greer, E.L.; Brunet, A. Different dietary restriction regimens extend lifespan by both independent and overlapping genetic pathways in C. elegans. Aging Cell 2009, 8, 113-127.
90. Haigis, M.C.; Guarente, L.P. Mammalian sirtuins-emerging roles in physiology, aging, and calorie restriction. Genes Dev. 2006, 20, 2913-2921.
91. Spindler, S.R. Biological effects of calorie restriction: From soup to nuts. Ageing Res. Rev. 2009.
92. Schulz, T.J.; Zarse, K.; Voigt, A.; Urban, N.; Birringer, M.; Ristow, M. Glucose restriction extends Caenorhabditis elegans life span by inducing mitochondrial respiration and increasing oxidative stress. Cell Metab. 2007, 6, 280-293.
93. Norrbom, J.; S, E.W.; Gustafsson, T.; Rundqvist, H.; Jansson, E.; Sundberg, C. Training response of mitochondrial transcription factors in human skeletal muscle. Acta Physiol. (Oxf) 2009.
94. McGinley, C.; Shafat, A.; Donnelly, A.E. Does Antioxidant Vitamin Supplementation Protect against Muscle Damage? Sports Med. 2009, 39, 1011-1032.
95. Gomez-Cabrera, M.C.; Domenech, E.; Romagnoli, M.; Arduini, A.; Borras, C.; Pallardo, F.V.; Sastre, J.; Vina, J. Oral administration of vitamin C decreases muscle mitochondrial biogenesis and hampers training-induced adaptations in endurance performance. Am. J. Clin. Nutr. 2008, 87, 142-149.
96. Onyango, I.G.; Lu, J.; Rodova, M.; Lezi, E.; Crafter, A.B.; Swerdlow, R.H. Regulation of neuron mitochondrial biogenesis and relevance to brain health. Biochim. Biophys. Acta 2009.
97. Ji, L.L.; Gomez-Cabrera, M.C.; Vina, J. Exercise and hormesis: Activation of cellular antioxidant signaling pathway. Ann. N. Y. Acad. Sci. 2006, 1067, 425-435.
98. Anekonda, T.S.; Reddy, P.H. Neuronal protection by sirtuins in Alzheimer's disease. J. Neurochem. 2006, 96, 305-313.
99. Guarente, L. Sirtuins in aging and disease. Cold Spring Harb. Symp. Quant. Biol. 2007, 72, 483-488.
100. Harikumar, K.B.; Aggarwal, B.B. Resveratrol: A multitargeted agent for age-associated chronic diseases. Cell Cycle 2008, 7, 1020-1035.
101. Bogacka, I.; Xie, H.; Bray, G.A.; Smith, S.R. Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes 2005, 54, 1392-1399.
102. Ghosh, S.; Patel, N.; Rahn, D.; McAllister, J.; Sadeghi, S.; Horwitz, G.; Berry, D.; Wang, K.X.; Swerdlow, R.H. The thiazolidinedione pioglitazone alters mitochondrial function in human neuron-like cells. Mol. Pharmacol. 2007, 71, 1695-1702.
103. Strum, J.C.; Shehee, R.; Virley, D.; Richardson, J.; Mattie, M.; Selley, P.; Ghosh, S.; Nock, C.; Saunders, A.; Roses, A. Rosiglitazone induces mitochondrial biogenesis in mouse brain. J. Alzheimers Dis. 2007, 11, 45-51.
104. Risner, M.E.; Saunders, A.M.; Altman, J.F.; Ormandy, G.C.; Craft, S.; Foley, I.M.; Zvartau-Hind, M.E.; Hosford, D.A.; Roses, A.D. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 2006, 6, 246-254.
105. Ferguson, E.C.; Rathmell, J.C. New roles for pyruvate kinase M2: Working out the Warburg effect. Trends Biochem. Sci. 2008, 33, 359-362.
106. Feron, O. Pyruvate into lactate and back: From the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother. Oncol. 2009, 92, 329-333.
107. Vander Heiden, M.G.; Cantley, L.C.; Thompson, C.B. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 2009, 324, 1029-1033.